The age of diagnostic coronary angiography is over

Br J Cardiol 2017;24:(3)doi:http://doi.org/10.5837/bjc.2017.017 Leave a comment
Click any image to enlarge
Authors:
First published online July 18th 2017

This article won first prize in the recent British Junior Cardiologists’ Association (BJCA) essay competition.

Coronary angiography stubbornly bucks the hospital-wide trend to non-invasive diagnostic tests. New imaging technologies offer paths to better ways to investigate and manage ischaemic heart disease. 

The problem

Diagnostic coronary angiography died some time ago, so why has it still not yet been buried alongside the exploratory laparotomy? The problem is clear: despite over half a century of experience, almost two-thirds of those undergoing elective diagnostic angiograms do not have obstructive coronary artery disease.1 Even in contemporary National Health Service (NHS) cardiac catheter laboratories, non-flow limiting coronary disease or angiographically normal coronary arteries remain common findings. Coronary angiography is now, arguably, the last invasive procedure to be performed with primarily diagnostic intent on this scale. How do we move to a situation in which invasive angiography is instead performed primarily to deliver therapeutic intervention, while identifying patients suitable for reassurance, medical therapy or surgery long before they reach the cath lab?

In 2017, computed tomography (CT) straightforwardly offers the best alternative to invasive angiography for the anatomical assessment of epicardial coronary disease. Rapid advances in row detector width, the introduction of dual sources, and new image reconstruction protocols now enable high-resolution, single-heartbeat coronary imaging with sub-millisievert doses, though clinical uptake in the UK is inconsistent and lags behind European, Asian and North American centres. One reason for this is the perception that standard CT angiography shares the same inherent limitation as standard invasive angiography: the inability to confidently determine which epicardial coronary stenoses of intermediate severity will benefit from intervention. A lesion of intermediate severity on CT, therefore, frequently results either in an invasive angiogram (with or without fractional flow reserve [FFR] assessment) or a further non-invasive test; CT computational estimates of FFR2 and perfusion imaging3 are not yet widely available or accepted by referring clinicians. As a result, the use of functional imaging tests, which indirectly assess myocardial ischaemia by measuring surrogate markers, such as perfusion or regional wall motion during vasodilator, inotropic, or exercise stress (table 1), remains high.

Lewis Table 1. Overview of currently available functional imaging tests
Table 1. Overview of currently available functional imaging tests

The challenge

The drive for better non-invasive ischaemia tests to replace diagnostic angiography is a significant technical challenge, which stems from the paradigm that it is the response of myocardium to ischaemia, rather than plaque appearances, which primarily determines the clinical response to intervention.4,5 It follows that the ideal non-invasive test would combine coronary anatomy with a reliable assessment of inducible myocardial ischaemia. Important limitations of the routinely available functional tests within the cardiologist’s armamentarium (stress echocardiography, perfusion cardiovascular magnetic resonance imaging [MRI], single-photon emission computed tomography–myocardial perfusion imaging [SPECT-MPI]) include largely qualitative readouts, subjective interpretation, and technical difficulties in key patient groups (e.g. obesity). The possibility of missing balanced ischaemia remains a concern to clinicians referring patients for some of these tests. Arguably, no functional ischaemia test commands the confidence of cardiologists to the same degree as does the coronary angiogram, but can even invasive angiography with FFR assessment truly be considered a ‘gold-standard’ test for myocardial ischaemia?

Although routinely validated against one another,6 angiography, perfusion and wall-motion assessments all measure different physiological parameters as surrogate markers of myocardial ischaemia. It is, therefore, not surprising that discrepancies between the findings of these tests exist; an inducible perfusion defect due to microvascular rather than epicardial coronary disease will be classified as a ‘false-positive’ if angiography with FFR is the reference standard and vice versa. If myocardial ischaemia truly underlies clinical response to treatment, the ideal non-invasive test should provide a quantitative measure of earlier and more fundamental measures of ischaemia than late downstream consequences, such as hypokinesia or electrocardiographic abnormalities. Although still technically a measure of perfusion rather than ischaemia, cardiac positron emission tomography (PET) using tracers, such as rubidium-82, offers advantages over commonly available functional tests, including quantitation of myocardial blood flow, rapid acquisition times, and the opportunity to assess coronary calcium during the low-dose attenuation correction CT.7 However, the interplay between the degree of inducible hypoperfusion and true myocardial ischaemia may vary between patients, and a novel MRI technology may offer benefits beyond even PET for assessing the earliest molecular responses of the myocardium to ischaemia.

Emerging technology

The heart, a transducer of chemical to mechanical energy, requires a continuous and matched supply of metabolic fuels (such as fat and glucose) and oxygen to sustain the rapid cellular energy cycling processes that sustain pump function.8 Within seconds of the interruption of the fine balance between cardiac work and oxygen delivery, a comprehensive shift in the myocardial metabolic programme occurs. Along with other signals, the reduced forms of cofactors, including nicotinamide adenine dinucleotide (NADH), accumulate in mitochondrial and then cytosolic spaces, shifting cardiac energy metabolism away from oxidative metabolism and towards oxygen-sparing anaerobic glycolysis. These ancient and highly conserved reactions drive the conversion of cytosolic pyruvate to lactate to preserve cardiac energetics and maintain pump function. Hyperpolarised carbon-13 MRI is an emerging technology in which the magnetic properties of externally prepared substrates are dramatically enhanced to create tracers with huge, though short-lived, increases in MRI signal.9 By administering hyperpolarised pyruvate to humans, it is now possible to measure the regional interconversion of myocardial pyruvate, bicarbonate and lactate at high resolution, using an essentially standard MRI scanner (figure 1).10 In addition to mapping regional ischaemia-induced lactate production, hyperpolarised pyruvate also offers mapping of myocardial ischaemic pH shifts by assessing the carbonic anhydrase dependent interconversion of hyperpolarised bicarbonate and carbon dioxide (figure 1, panel c).11 This technology, therefore, paves the way to an earlier and more fundamental assessment of cardiac ischaemia than has previously been possible with any other technique.12 Parallel advances in cardiac MRI offer ever-improving images of the proximal coronary arteries, alongside the routinely available high-quality assessments of wall motion, first-pass perfusion,13 and viability to complement hyperpolarised metabolite imaging, which could add just 5–10 minutes to the standard imaging protocol.

Is the age of elective diagnostic coronary angiography truly over?

No, and this is because no widely available non-invasive imaging test offers a truly compelling ‘one-stop-shop’ for coronary anatomy and myocardial ischaemia. New hybrid imaging tests, such as coronary CT with rubidium-82 PET or coronary MRI angiography with hyperpolarised lactate mapping, however, offer a vision of a future in which the diagnostic performance of the invasive coronary angiogram for true ischaemia is not simply approached, but may be exceeded. A more focused programme of targeted intervention restricted to defined target plaques proven to be causing downstream ischaemia would be expected to lead to better clinical outcomes from these procedures, as well as removing the low-but-not-zero risks of invasive angiography from those without true ischaemia.

In developing these non-invasive techniques in an arterial system as small, mobile, and technically challenging as the coronary tree, there exists the opportunity for cardiologists not merely to catch up with the road-mapped procedures of neurological and vascular interventionists. Rather, cardiologists should develop these, and other advances, to lead the definition of new diagnostic and therapeutic paradigms for diseases resulting from the acute and long-term consequences of ischaemia.

Key messages

  • Treatment of myocardial ischaemia is thought to underlie therapeutic benefit from coronary intervention, though current non-invasive imaging tests cannot truly assess myocardial ischaemia, resulting in a low diagnostic yield from invasive angiography
  • Hyperpolarised magnetic resonance imaging (MRI) is an emerging technology in which huge signal-to-noise increases can be used to enable assessment of the earliest molecular responses of the myocardium to ischaemia

Conflict of interest

None declared.

References

1. Preik M, Kelm M, Strauer B et al. Low diagnostic yield of elective coronary angiography. N Engl J Med 2010;363:92–5. https://doi.org/10.1056/NEJMc1004220

2. Ko BS, Cameron JD, Munnur RK et al. Noninvasive CT-derived FFR based on structural and fluid analysis: a comparison with invasive FFR for detection of functionally significant stenosis. JACC Cardiovasc Imaging 2016;online first. https://doi.org/10.1016/j.jcmg.2016.07.005

3. Siontis KC, Gersh BJ, Williamson EE, Foley TA, Askew JW, Anavekar NS. Diagnostic performance of myocardial CT perfusion imaging with or without coronary CT angiography. JACC Cardiovasc Imaging 2016;9:322–4. https://doi.org/10.1016/j.jcmg.2015.02.016

4. Boden WE, O’Rourke RA, Teo KK et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503–16. https://doi.org/10.1056/NEJMoa070829

5. Erne P, Schoenenberger AW, Burckhardt D et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA 2007;297:1985–91. https://doi.org/10.1001/jama.297.18.1985

6. Erhard MI, Rieber MJ, Jung MP et al. The validation of fractional flow reserve in patients with coronary multivessel disease: a comparison with SPECT and contrast-enhanced dobutamine stress echocardiography. Zeitschrift für Kardiologie 2005;94:321–7. https://doi.org/10.1007/s00392-005-0213-6

7. McArdle BA, Dowsley TF, Wells GA, Beanlands RS. Does rubidium-82 PET have superior accuracy to SPECT perfusion imaging for the diagnosis of obstructive coronary disease?: A systematic review and meta-analysis. J Am Coll Cardiol 2012;60:1828–37. https://doi.org/10.1016/j.jacc.2012.07.038

8. Taegtmeyer H, Young ME, Lopaschuk GD et al. Assessing cardiac metabolism. A scientific statement from the American Heart Association. Circ Res 2016;118:1659–701. https://doi.org/10.1161/RES.0000000000000097

9. Ardenkjær-Larsen JH, Fridlund B, Gram A et al. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc Nat Acad Sci 2003;100:10158–63. https://doi.org/10.1073/pnas.1733835100

10. Cunningham CH, Lau JY, Chen AP et al. Hyperpolarized 13C metabolic MRI of the human heart: initial experience. Circ Res 2016;119:1177–82. https://doi.org/10.1161/CIRCRESAHA.116.309769

11. Lau AZ, Miller JJ, Tyler DJ. Mapping of intracellular pH in the in vivo rodent heart using hyperpolarized [1-13C] pyruvate. Magn Reson Med 2017;77:1810–17. https://doi.org/10.1002/mrm.26260

12. Schroeder MA, Clarke K, Neubauer S, Tyler DJ. Hyperpolarized magnetic resonance. A novel technique for the in vivo assessment of cardiovascular disease. Circulation 2011;124:1580–94. https://doi.org/10.1161/CIRCULATIONAHA.111.024919

13. Greenwood JP, Maredia N, Younger JF et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet 2012;379:453–60. https://doi.org/10.1016/S0140-6736(11)61335-4

THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT